2026 Third Quarter Update
CAPITAL Following the start of our FIH, we decided to reopen our Seed Prime II round and extend it by up to an additional $3M.
Nanochon Performs First Case in the Chondrograft™ First in Human Clinical Study
Baltimore, MD, September 2, 2026 – Nanochon, a medical device company developing Chondrograft™, a novel 3D-printed patented implant for the treatment of articular cartilage defects
Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™
August 14, 2026 – Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee,
2026 Second Quarter Update
CAPITAL After the close of our Seed Prime II round in January, we received significant interest from follow-on investors, so we extended the round through
Nanochon Turns 10
Dear Colleagues, Nanochon’s 10-year anniversary represents a time for us to reflect on the immense progress we’ve made over the last decade and thank those
2026 First Quarter Update
CAPITAL Following the formal close of our Seed Prime II round at $4.1M (pre-money valuation: $24M) announced in January, additional funds bring our total capital
Nanochon Abstract Presented at AAOS 2026
Charlotte K Barton1, Kathryn Seabaugh 1, Ben Gadomski 2, Kevin Labus 2, Ben Holmes 3, Nathan Castro 3, Mike Hawes 4, Brad B Nelson 1,
2025 Fourth Quarter Update
Capital Nanochon has closed another oversubscribed round, bringing in new capital and increasing the total amount raised to $4.1M. This round was led by Ecphora
UVAToday Features Nanochon
This article was originally published on UVA Today This Alum’s Tech May Revolutionize Knee Joint Replacements Benjamin Holmes can pinpoint the exact moment he fell
Nanochon closes $4.1M Seed Prime II Funding Round
WASHINGTON, January 12, 2026 — Nanochon, a Washington, DC-based orthopedic device company developing an implant for treating articular cartilage defects in the knee, has secured